sellWeak cluster of 7
Kathleen Tregoning sold $260k of CERE
See Remarks at Cerevel Therapeutics Holdings, Inc.. 6,288 shares at an average of $41.42, traded Dec 20, 2023, filed Dec 21, 2023.
Warning score
38Value
$260k
6,288 shares
Holdings after
7,516
-46% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +13Trade size$260k at market
- +10Share of holdings soldSold 46% of holdings
- +15Cluster7 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-23-072363, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2023 | MOption exercise Common Stock | +13,804 | - | - | 13,804 | Dec 21, 2023 |
| Dec 20, 2023 | SOpen-market sale Common Stock | -6,288 | $41.42 | $260k | 7,516 | Dec 21, 2023 |
| Dec 19, 2023 | MOption exercise Restricted Stock Unitsderivative | -13,804 | $0.00 | $0 | 0 | Dec 21, 2023 |
Related signals
Other insiders at Cerevel Therapeutics Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 23Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $104k 2,506 shares | -14% | |
| 27Weak | Cerevel Therapeutics Holdings, Inc. | John Renger Chief Scientific Officer | $90k 2,161 shares | -25% | |
| 40Moderate | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -95% | |
| 21Weak | Cerevel Therapeutics Holdings, Inc. | Ramiro Sanchez Chief Medical Officer | $425k 10,000 shares | -41% | |
| 35Weak | Cerevel Therapeutics Holdings, Inc. | Kenneth DiPietro Chief Human Resources Officer | $332k 8,000 shares | -24% | |
| 51Moderate | Cerevel Therapeutics Holdings, Inc. | Susan ALTSCHULLER Chief Financial Officer | $572k 13,808 shares | -45% | |
| 39Weak | Cerevel Therapeutics Holdings, Inc. | Scott Akamine Chief Legal Officer | $293k 7,072 shares | -49% | |
| 40Moderate | Cerevel Therapeutics Holdings, Inc. | Mark Bodenrader See Remarks | $327k 7,889 shares | -31% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.